Breakthrough technologies for continuous monitoring, diagnosis, and treatment optimization
Smartlens is redefining anterior segment disease management through breakthrough technologies that address critical unmet needs in continuous monitoring, diagnosis, and treatment optimization. Our flagship platform focuses on intraocular pressure (IOP) - the primary risk factor for glaucoma, the leading cause of irreversible blindness worldwide. By combining novel microfluidic technology with AI-enhanced diagnostics, we enable precise, real-time tracking and personalized care management.
Our integrated solution represents a paradigm shift in ophthalmic care, moving from episodic office visits to continuous, data-driven treatment across multiple anterior segment conditions. By fundamentally transforming how these diseases are monitored and treated, Smartlens enables early detection, improved outcomes, and broader access to specialist care.
The world's smallest wearable microfluidic device
Current glaucoma management relies on infrequent IOP measurements during office visits, missing critical pressure variations that can lead to irreversible vision loss.
Our flagship product miLens is a breakthrough, non-invasive device that enables remote monitoring of intraocular pressure (IOP) anywhere, at any time through a comfortable, electronics-free contact lens design.
Designed for diurnal monitoring, it works seamlessly with our AI-powered smartphone-based imaging system. miLens captures critical pressure variations missed by current quarterly or annual measurements, enabling early detection of dangerous IOP spikes for timely intervention.
AI-powered remote examination platform
Our Anterior Segment Monitoring Platform provides comprehensive monitoring of all anterior segment conditions including Dry Eye, Cataracts, Conjunctivitis, Blepharitis, Episcleritis, Scleritis, Pterygium, Anterior Uveitis, and Trauma.
All anterior segment exams can be performed through our AI-powered remote examination platform, facilitating telemedicine capabilities and standardizing disease assessment through AI-powered grading and enhanced monitoring.
By expanding specialist access across geographical barriers, our platform enables more efficient, accessible, and standardized eye care delivery.
Automated micro-dose medication delivery
A novel wearable device that addresses poor medication adherence and imprecise dosing in chronic eye diseases. The automated system delivers personalized micro-dose medications, with initial focus on glaucoma treatment.
Its unique micro-dosing technology enhances therapeutic efficacy while minimizing side effects common with traditional eye drops. The programmable platform optimizes treatment timing based on each patient's pressure patterns.
Designed for versatility across chronic eye conditions, THERx IQ's automated approach removes patient compliance barriers while ensuring optimal drug delivery.
AI/ML-powered analytics platform
AI/ML-powered platform unlocking insights from first-of-its-kind diurnal IOP monitoring and comprehensive imaging data. By integrating intraocular pressure patterns from miLens and standardized anterior segment imaging from our anterior segment platform, the system provides deeper understanding of disease progression.
The platform eliminates subjective variability through standardized, quantifiable measurements of both pressure data and structural changes. Integrating seamlessly with our monitoring technologies, it provides real-time risk stratification and data-driven analysis to inform treatment decisions.
The platform's predictive capabilities, enhanced by intraocular pressure monitoring and imaging analysis, enable early intervention by identifying high-risk patients before significant disease progression.
Stay updated with the latest news, clinical trial updates, and industry insights from Smartlens Health.
Visit our LinkedInOur technologies are advancing through U.S. pivotal trials, demonstrating strong clinical validation and practitioner interest.
Learn moreSign up to be the first to know when miLens becomes commercially available.
Get notified